News!
News for 'CYGX' - (CytoGenix Announces Award of SBIR Grant from the National Institutes of Health)
HOUSTON, Jun 26, 2008 (BUSINESS WIRE) -- CytoGenix, Inc. (CYGX), today
announced that the National Institute of Allergy and Infectious Diseases of NIH
has awarded a Phase I Small Business Innovation Research Grant (SBIR) to
CytoGenix, Inc. Dr. Frederic Kendirgi will be the principal investigator. The
grant entitled, "Novel DNA Manufacturing Process: Cell-Free Production and
Testing of a New Multivalent DNA Vaccine Against Human Influenza (H5N1)"
received an award of approximately $136,000.
Dr. Kendirgi comments, "The emergence of highly pathogenic avian influenza
viruses in domestic poultry and the increasing number of cases derived from
direct transmission of avian influenza viruses to humans are a significant
threat to public health. Currently, no robust vaccines against potentially
pandemic avian flu viruses are available to the general public.
Results from this grant may pave the way for a new generation of DNA vaccines
against influenza virus strains using our synDNA(SM) production process which
can be rapidly adapted to new viral strains. This acknowledgement of our
technology allows us to put this process to trial by focusing on a potential
medical emergency.
If successful, we hope to routinize our vaccine production platform and apply
the experience gathered to generate synDNA(SM) vaccine candidates against other
pathogen causing diseases such as malaria, AIDS or tuberculosis to which
effective vaccines prepared by conventional methods have shown disappointing
results."
Dr. Malcolm Skolnick, CytoGenix CEO adds, "Award of this peer reviewed,
competitive grant provides support for CytoGenix's ongoing research and
development efforts as well as external validation of the synDNA(SM) vaccine
technology. The Company will utilize the results from this Phase I grant to
develop our application for further funding in additional phases of the SBIR
program."
SAFE HARBOR: Except for statements of historical fact, the statements in this
press release are forward-looking. Such statements are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from the statements made. These factors include, but are not limited to, general
economic conditions, risks associated with the acceptance of new products,
competition, and other factors more fully detailed in the Company's filings with
the Securities and Exchange Commission. Additional information about CytoGenix
and its technology can be found on the website at www.cytogenix.com.
SOURCE: CytoGenix, Inc.
AI
